Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of CSL H1N1 Vaccine in Adults and Elderly
NCT00943488Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2009
- Primary completion
- Mar 2010
- Modality
- Live Attenuated Vaccines, Whole Inactivated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Influenza A (H1N1) vaccine in influenza, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Number of Participants Reporting Solicited Local Reactions Based on the Functional Grading Scale, Number of Participants Reporting Measured Injection Site Reactions of Swelling and Redness and 5 more. Started Aug 2009; status: completed.
02
Drugs
Influenza A (H1N1) vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00943488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00943488.